Seelos Therapeutics Retains Canaccord Genuity In Connection With Review Of Potential Partnerships And Collaborations
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics, Inc. (NASDAQ:SEEL) has retained Canaccord Genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities. The company has not guaranteed that this review will result in any partnerships or collaborations.
October 17, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seelos Therapeutics is exploring potential partnerships and collaborations, which could potentially lead to new opportunities for the company. However, there is no assurance of any resulting deals.
The news of Seelos Therapeutics exploring potential partnerships and collaborations could potentially lead to new opportunities for the company, which could have a positive impact on the company's stock. However, as there is no assurance of any resulting deals, the impact on the stock is uncertain at this point.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100